J de Leon1, J Barnhill, T Rogers, J Boyle, W H Chou, P J Wedlund. 1. University of Kentucky Mental Health Research Center at Eastern State Hospital and the University of Kentucky College of Pharmacy, Lexington 40508, USA. jdeleon@pop.uky.edu.us
Abstract
OBJECTIVE: The authors conducted a pilot study to develop preliminary data on the frequency of cytochrome P450-2D6 (CYP2D6) genotypes in state psychiatric hospital patients and to establish population sizes needed to determine potential clinical relevance in therapeutic outcome. METHOD: One hundred consecutive inpatients at Eastern State Hospital in Kentucky who provided informed consent were genotyped at the CYP2D6 locus during their hospital stay. RESULTS: Twelve of the patients were CYP2D6 deficient, and four carried the *1Xn or *2Xn allele associated with ultrarapid metabolism; all of these patients were Caucasian (N=87). The rate of deficiency in CYP2D6 expression in these Caucasian state psychiatric hospital patients (14%) was twice that of the U.S. population (7%). The patients with CYP2D6 deficiency also appeared more likely to experience side effects in response to CYP2D6 medications. CONCLUSIONS: This study, limited by a small number of subjects, suggests that one-fifth of Caucasians admitted to a state hospital in Kentucky had genotypes associated with extremes in CYP2D6 activity that may have affected their response to CYP2D6 medications.
OBJECTIVE: The authors conducted a pilot study to develop preliminary data on the frequency of cytochrome P450-2D6 (CYP2D6) genotypes in state psychiatric hospital patients and to establish population sizes needed to determine potential clinical relevance in therapeutic outcome. METHOD: One hundred consecutive inpatients at Eastern State Hospital in Kentucky who provided informed consent were genotyped at the CYP2D6 locus during their hospital stay. RESULTS: Twelve of the patients were CYP2D6 deficient, and four carried the *1Xn or *2Xn allele associated with ultrarapid metabolism; all of these patients were Caucasian (N=87). The rate of deficiency in CYP2D6 expression in these Caucasian state psychiatric hospital patients (14%) was twice that of the U.S. population (7%). The patients with CYP2D6deficiency also appeared more likely to experience side effects in response to CYP2D6 medications. CONCLUSIONS: This study, limited by a small number of subjects, suggests that one-fifth of Caucasians admitted to a state hospital in Kentucky had genotypes associated with extremes in CYP2D6 activity that may have affected their response to CYP2D6 medications.
Authors: Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann Journal: Drug Saf Date: 2006 Impact factor: 5.606
Authors: Cynthia A Prows; Todd G Nick; Shannon N Saldaña; Sanjeev Pathak; Chunyan Liu; Kejian Zhang; Zachary S Daniels; Alexander A Vinks; Tracy A Glauser Journal: J Child Adolesc Psychopharmacol Date: 2009-08 Impact factor: 2.576
Authors: Wim J Tamminga; Johan Wemer; Berend Oosterhuis; Anthonius de Boer; Stan Vranckx; Ben F H Drenth; Rokus A de Zeeuw; Lou F M H de Leij; Jan H G Jonkman Journal: Eur J Clin Pharmacol Date: 2003-03-18 Impact factor: 2.953